Latest Earnings Results: Q2 '26
Estimated EPS
$1.01
Reported EPS
$1.26
Surprise
+25.12%
Estimated Rev
$2.66B
Reported Rev
$2.85B
Surprise
+7.26%
• Reported GAAP EPS of $0.69 up 72.50% YoY • Reported revenue of $2.01B down -20.66% YoY • Bausch Health Companies Inc. raised its full-year 2026 guidance, now targeting consolidated revenues of $10.790-$11.040 billion, Adjusted EBITDA of $4.050-$4.175 billion, and Adjusted Cash Flows from Operations of $1.400-$1.475 billion.
Bullish Takeaway
Bausch Health Companies Inc. achieved thirteen consecutive quarters of growth, highlighted by strong revenue and Adjusted EBITDA performance, robust cash flow generation, and successfully improved debt maturity profiles across the business.
Bearish Takeaway
Bausch Health Companies Inc. faces material risks from potential tariff impacts, future regulatory pricing pressures on Xifaxan under the Inflation Reduction Act, and the ongoing burden of its significant debt load.
Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q3 '26 | $1.23 | -- | -- | N/A |
Q2 '26 | $1.01 | $1.26 | 25.12% | BEAT |
Q1 '26 | $0.67 | $0.78 | 16.13% | BEAT |
Q4 '25 | $1.20 | $1.08 | -10.58% | MISSED |
Q3 '25 | $1.06 | $1.16 | 9.53% | BEAT |